GE vs IRTC: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
GE is the larger of the two ($322.97B market cap): the incumbent the market prices for continued execution (33.56x forward earnings, beta 1.41). IRTC is the smaller challenger ($3.18B), actually pricier on forward earnings (61.63x): more room to run, but more to prove. If you believe in growth, IRTC fits: analysts expect its revenue to rise 20% next year, against 12% for GE. If you believe in paying less for profit, GE fits: it trades at 33.56x forward earnings, against 61.63x for IRTC.
GE vs IRTC: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | GE | IRTC | What it tells you |
|---|---|---|---|
| Market cap | $322.97B | $3.18B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 33.56 | 61.63 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.41 | 1.47 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 36% of range | 11% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 18.43 | 17.87 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: GE is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how GE and IRTC affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GE and IRTC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GE and IRTC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does GE Aerospace (GE) do?
GE Aerospace is the aviation business of the former General Electric conglomerate, which split into three independent companies, with GE Aerospace retaining the GE ticker. It is one of the world's largest makers of commercial and military jet engines. GE Aerospace designs, manufactures, and services engines that power a large share of the global airliner fleet, including through CFM International, its long-running joint venture with France's Safran that produces the best-selling engines for narrowbody aircraft like the Boeing 737 and Airbus A320 families. The company makes money from selling new engines and, more importantly, from a highly profitable aftermarket of spare parts, maintenance, repair, and long-term service agreements that generate recurring revenue over each engine's decades-long life. GE Aerospace also supplies military engines and avionics. Headquartered in Cincinnati, Ohio, it benefits from a massive installed base of engines, strong air-travel demand, and the lucrative razor-and-blades economics of jet engine servicing.
What does iRhythm Technologies (IRTC) do?
iRhythm makes the Zio service, a small adhesive patch that records a patient's heart rhythm continuously for up to 14 days and pairs it with AI-assisted analysis to detect arrhythmias such as atrial fibrillation. The device replaced the older Holter-monitor workflow (short-window, wired recorders) with a longer, more comfortable, water-resistant patch that is mailed back for algorithmic analysis and a physician report. Zio has become the most widely prescribed ambulatory ECG monitor in the US, and iRhythm is extending the franchise with mobile cardiac telemetry, international expansion, and adjacencies such as sleep apnea and primary-care risk stratification. In October 2026 it completed the acquisition of VitalConnect, a wearable-biosensor company with a 30-day mobile cardiac telemetry platform that can track up to 11 physiological parameters, for $237.5 million in cash plus up to about 423,000 shares.
GE vs IRTC: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- GE drivers: Aftermarket services engine; Dominant narrowbody position.
- IRTC drivers: Zio volume growth and category leadership; Mobile cardiac telemetry: Zio MCT plus VitalConnect.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: GE Aerospace is exposed to the cyclical aviation industry, where downturns, pandemics, or shocks to air travel can sharply reduce flight hours and aftermarket revenue. For IRTC, regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT.
GE or IRTC: which should you pick?
If the story you believe is GE's (Aftermarket services engine), GE is the more direct way to own it; if it is IRTC's (Zio volume growth and category leadership), IRTC is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GE and IRTC guides.
GE vs IRTC: the full fundamentals
GE. GE Aerospace is valued as a high-quality aviation franchise, at roughly 36x trailing and 34x forward earnings and about 6.2x sales as of November 2026. That premium rests on aftermarket profits, narrowbody leadership and revenue growth in the mid-teens, and it leaves the stock sensitive to aviation cyclicality and delivery execution. The 21-analyst mean target is about $378; Q4 results, expected around January 21, 2027, are forecast to show EPS near $2.35.
IRTC. At about $95 on November 20, 2026, IRTC trades at roughly 3.7 times trailing sales and 62 times forward earnings, a lower sales multiple than earlier in the year after a 46% drop in the share price even as revenue kept growing in the mid-teens. GAAP earnings are still negative (no trailing P/E), so the valuation leans on volume growth, margin expansion and the MCT strategy more than current profits. The mean analyst target among 15 tracked by Yahoo was about $153, well above the price, and the board's decision to buy back up to $200 million of stock signals how management views the drop.
Headline figures (approximate, November 2026): GE shows revenue (ttm) ~$52.6 billion, revenue growth (q3 2026, yoy) ~16%, operating margin ~20%, net income (ttm) ~$9.2 billion; IRTC shows revenue (ttm) ~$854M; 2026 guidance midpoint ~$892.5M, q3 2026 revenue growth ~15% YoY (~$221.6M, slightly below consensus), gross / operating margin (ttm) ~72% / ~4.5%, adjusted ebitda (q3 2026) ~$51M, ~23% margin (record).
The bottom line: GE vs IRTC
GE and IRTC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined GE and IRTC exposure against your real portfolio. It is not an investment adviser.
Wondering how GE or IRTC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about GE Aerospace
Ask Walnut's AI anything about GE and see how it fits what you own.
FAQ
What is the difference between GE and IRTC?
+
GE Aerospace is the aviation business of the former General Electric conglomerate, which split into three independent companies, with GE Aerospace retaining the GE ticker. iRhythm makes the Zio service, a small adhesive patch that records a patient's heart rhythm continuously for up to 14 days and pairs it with AI-assisted analysis to detect arrhythmias such as atrial fibrillation. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is GE or IRTC the better stock?
+
Neither is universally better. GE is the larger incumbent; IRTC is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, GE or IRTC?
+
On forward P/E (as of November 2026), GE trades at 33.56x and IRTC at 61.63x, so GE is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both GE and IRTC?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of GE vs IRTC?
+
GE: GE Aerospace is exposed to the cyclical aviation industry, where downturns, pandemics, or shocks to air travel can sharply reduce flight hours and aftermarket revenue. It depends heavily on the health of Boeing and Airbus production rates, and supply chain constraints have limited engine deliveries. Engine programs are technically complex, and quality or durability issues can be costly. The CFM joint venture ties results partly to Safran. New engine programs require heavy upfront investment with long payback. Competition from Pratt and Whitney and Rolls-Royce is intense. The stock's valuation has risen significantly, leaving it sensitive to any slowdown in the aviation cycle or execution missteps. At about 36x trailing and 34x forward earnings and roughly 29x EV/EBITDA as of November 2026, the price assumes continued double-digit growth; the 10.5% three-month decline came as sentiment on the aerospace and defense group softened, even though the company beat Q3 estimates and raised guidance. Debt of about $20.6 billion against $9.8 billion of cash is manageable but not negligible. US lawmakers are also pressing to restrict investment in China's aerospace sector, a policy area that could touch engine exports and joint programs. IRTC: Regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. Reimbursement is the other central risk, since a large share of revenue depends on CMS and commercial payer rates that can be cut or restructured. Growth is slowing (about 15% in Q3 2026 after about 20% in Q2), and management warned that VitalConnect integration may keep Zio AT sales soft for a quarter or two; Citi downgraded the stock after the report. Data security became a live issue in 2026: unauthorized individuals accessed and downloaded patient information (names, contact details, insurance numbers, dates of birth) from third-party-hosted business applications between June 3 and June 8, 2026, and iRhythm began notifying affected patients on October 2. The company says it does not expect a material financial impact and saw no effect on its devices or patient safety, but breaches can bring litigation and regulatory scrutiny. The balance sheet carries about $726 million of debt against about $561 million of cash at September 30, 2026, and the $100 million accelerated buyback will draw that cash down further. The company is still loss-making on a GAAP basis and trades at a premium earnings multiple, so any volume slowdown, pricing pressure or launch delay could compress the stock further, as its 46% drop in 2026 shows. Competition from larger, better-capitalized players (Philips, Boston Scientific) adds further risk, and medtech reimbursement and regulatory outcomes are difficult to predict.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell GE or IRTC; figures are approximate and dated (as of November 2026). Verify current data before investing.